Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for 11,800 crore. NTK alleges Daiichi Sankyo blocked its 2018 open offer for Fortis Healthcare. Daiichi Sankyo denies these claims. NTK seeks damages and an injunction against Daiichi Sankyo's statements. The next court hearing is scheduled for July 11.

Drug regulatory authority mandates disposal of unused opioid drugs and painkillers. This action aims to prevent misuse and health risks. Central Drugs Standard Control Organisation has listed 17 harmful medicines for disposal. Some drugs should be flushed, while others can be collected through 'drug take back' programs. Unscientific disposal causes environmental pollution and drug resistance.

India is developing a structured critical care framework to bridge infrastructure and human resource gaps. Led by NITI Aayog, the initiative will define resource allocation, patient prioritization, and standards for critical care units nationwide. This aims to improve domestic healthcare and attract medical tourists, addressing current imbalances and talent drain while preparing for future health crises.

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously 1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market reach.

Quadria Capital, an Asia healthcare-focused private equity firm, has successfully raised $1.07 billion for its third fund, surpassing its initial $800 million target. The oversubscribed fund will allocate approximately 60% of its capital to India, with the remainder invested in ASEAN countries. This fund also marks the first time Quadria Capital has received significant domestic capital commitments from Indian institutions.

Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.

Fast forward to 2025, and a whole new market has emerged gummies to enhance your hair health, powders to boost collagen, liquid for gut, pills for womens perimenopause hormonal imbalance, magnesium tablets for better sleep, testosterone boosters, capsules with calming properties and vegan versions of all these.

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.

US Health Secretary Robert F. Kennedy's plan to Make America Healthy Again faces challenges as government cuts eliminate over a dozen data-gathering programs tracking deaths and diseases. The CDC lost experts monitoring areas like abortions, lead poisoning, and violence. Critics warn that these cuts will hinder the ability to understand and address health issues effectively.

The introduction of weight-loss medications like Mounjaro and Wegovy in India may lead to a decrease in bariatric surgeries as obese individuals with a BMI of 30-35 may opt for drugs first. While surgeries can result in 70-80% weight loss, drugs offer a less invasive option, though potentially less effective at 15-20%.

In a devastating incident, an Australian woman unknowingly carried and gave birth to another couple's baby due to a mix-up at a Monash IVF clinic in Brisbane. The clinic attributed the error to a human error during the embryo transfer process.

Donald Trump announced a forthcoming major tariff on pharmaceutical imports, aiming to incentivize drug companies to relocate operations to the U.S. He also stated he warned Taiwan Semiconductor Manufacturing Company (TSMC) about potential taxes if they didn't establish U.S. plants. Trump criticized the Biden administration's $6.6 billion grant to TSMC's U.S.